Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 8:35 a.m.

    📋 Turning Point Therapeutics, Inc. (TPTX) - Regulatory Update

    Filing Date: 2022-06-21

    Accepted: 2022-06-21 16:01:03

    Event Type: Regulatory Update

    Event Details:

    Turning Point Therapeutics (the company was acquired by Bristol-Myers Squibb Company (NYSE : BMY)) (TPTX) Announces Regulatory Update Turning Point Therapeutics (the company was acquired by Bristol-Myers Squibb Company (NYSE : BMY)) (TPTX) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: None Clinical Development:

    🔬 Clinical Development Pipeline (Turning Point Therapeutics, Inc.):

    Product Type Development Stage Therapeutic Area Source
    elzovantinib (TPX-0022) DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Turning Point Therapeutics (the company was acquired by Bristol-Myers Squibb Company (NYSE : BMY))
    • CIK: 0001595893
    • Ticker Symbol: TPTX
    • Period End Date: 2022-06-16
    • Document Type: 8-K

Search

News categories